CBT for Insomnia Slows Biological Aging in Older Adults
A randomized trial finds CBT-I measurably slows the pace of epigenetic aging in adults over 60 compared to sleep education.
Summary
Researchers from UCLA tested whether treating insomnia with cognitive behavioural therapy (CBT-I) could slow biological aging in older adults. Using DNA methylation-based epigenetic clocks — specifically DunedinPACE — they compared 47 adults receiving CBT-I against 45 receiving sleep education therapy over up to 30 months. Adults who received CBT-I showed a significantly slower pace of biological aging than those in the control group. CBT-I also achieved full insomnia remission more than twice as often as sleep education (34% vs 13%). Two other epigenetic clocks — GrimAge and PCPhenoAge — did not show statistically significant differences. The findings suggest that treating insomnia with a structured psychological intervention may be a practical, non-pharmacological strategy for slowing the biological aging process in older, clinically vulnerable populations.
Detailed Summary
Insomnia is increasingly recognized not just as a sleep problem but as a potential accelerant of biological aging — yet until now, little evidence existed showing that treating insomnia could actually slow that aging process at the molecular level. This study from UCLA's Cousins Center for Psychoneuroimmunology addresses that gap directly, with results that have significant implications for longevity medicine.
Researchers conducted a secondary analysis of a randomized controlled trial (NCT01641263) enrolling adults aged 60 and older who met diagnostic criteria for insomnia disorder. Participants were randomized to either cognitive behavioural therapy for insomnia (CBT-I) — the gold-standard psychological treatment — or sleep education therapy (SET), an active control. Biological aging was assessed using DNA methylation-based epigenetic clocks measured from blood samples at baseline and at a follow-up visit 20–39 months later.
The primary finding was striking: adults receiving CBT-I showed a significantly slower pace of biological aging as measured by DunedinPACE (effect size -0.02, FDR-adjusted p=0.03) compared to those receiving SET. DunedinPACE is considered one of the most sensitive epigenetic clocks for detecting real-time changes in aging rate. Two other clocks — GrimAge and PCPhenoAge — did not reach statistical significance, though trends favored CBT-I. CBT-I also produced full insomnia remission in 34% of participants versus only 13% in the SET group, underscoring its clinical superiority.
The implications are compelling: a behavioral, drug-free intervention routinely available through trained clinicians may slow measurable biological aging. For a population in which insomnia is prevalent and often undertreated, this reframes sleep therapy as a potential longevity intervention rather than merely a comfort measure.
Caveats include the modest sample size, the fact that only one of three epigenetic clocks reached significance, and that this is a secondary analysis rather than a pre-registered primary endpoint. The summary is based on the abstract only.
Key Findings
- CBT-I significantly slowed the pace of biological aging (DunedinPACE) vs sleep education in adults over 60.
- Full insomnia remission was achieved in 34% of CBT-I participants vs only 13% in the sleep education group.
- Effect was specific to DunedinPACE; GrimAge and PCPhenoAge did not reach statistical significance.
- Epigenetic aging benefits emerged over a 20–39 month follow-up period in community-dwelling older adults.
- Results suggest treating insomnia is a non-pharmacological strategy for slowing biological aging.
Methodology
Secondary analysis of a single-site RCT (NCT01641263) enrolling adults aged 60+ with DSM-IV insomnia disorder, randomized to CBT-I (n=47) or sleep education therapy (n=45). Epigenetic biological age was assessed from peripheral blood mononuclear cells at baseline and 20–39 month follow-up using DunedinPACE, GrimAge, and PCPhenoAge clocks. Follow-up times beyond 30 months were winsorised to 30 months.
Study Limitations
The sample size was modest (n=92 with paired epigenetic data), limiting statistical power, particularly for the clocks that trended but did not reach significance. Only one of three epigenetic clocks showed a statistically significant difference, raising questions about which aging pathways are most affected. This is a secondary analysis rather than a pre-specified primary outcome, and the summary is based on the abstract only, so full methodological details could not be reviewed.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: